1,2,3,4-Tetrahydro-naphthalene-1-carboxylic acid methoxy-methyl-amide | 95092-09-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1,2,3,4-Tetrahydro-naphthalene-1-carboxylic acid methoxy-methyl-amide
• 英文别名: 1,2,3,4-Tetrahydro-N-methoxy-N-methyl-1-naphthalenecarboxamide；N-methoxy-N-methyl-1,2,3,4-tetrahydronaphthalene-1-carboxamide
• CAS: 95092-09-4
• 化学式: C₁₃H₁₇NO₂
• 分子量: 219.283
• InChiKey: RLXLZYHFTIATIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,2,5,5-tetrametyl-1-aza-2,5-disilacyclopentane-1-propyl magnesium bromide 、 1,2,3,4-Tetrahydro-naphthalene-1-carboxylic acid methoxy-methyl-amide 生成 2-(1,2,3,4-Tetrahydro-naphthalen-1-yl)-pyrrolidine
  参考文献：
  名称：

  一种新型的三碳氨基格氏试剂：其在高效吡咯烷合成中的用途

  摘要：

  已经开发了一种新型的伯氨基保护的格氏试剂。2,2,5,5-四甲基-1-氮杂-2,5-二硅环戊烷-1-丙基溴化镁1a。在2-取代的吡咯烷的合成中说明了其有用性。

  DOI：

  10.1016/s0040-4039(01)81581-1

文献信息

• Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles
  申请人：Galley Guido

  公开号：US20070197620A1

  公开（公告）日：2007-08-23

  The present invention relates to a method for treating a disorder selected from depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R 1 , R 2 , Q, W, X, Y, m, and n are as defined in the specification d or not; and their pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers and tautomeric forms. The invention also relates to novel compounds of formula I, compositions containing them, and methods for their preparation.

  本发明涉及一种治疗选自抑郁症、焦虑症、双相情感障碍、注意力缺陷多动症、压力相关疾病、精神疾病如精神分裂症、神经疾病如帕金森病、神经退行性疾病如阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用和代谢性疾病如进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和同化障碍、体温稳态障碍和功能障碍、睡眠和昼夜节律障碍以及心血管疾病的方法，包括向个体施用化合物I的治疗有效量，其中化合物I的公式为R1，R2，Q，W，X，Y，m和n如规范中所定义的，或不定义；以及它们的药物活性盐，外消旋混合物，对映异构体，光学异构体和互变异构体形式。本发明还涉及公式I的新化合物，包含它们的组合物以及其制备方法。
• METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES
  申请人：Galley Guido

  公开号：US20120071506A1

  公开（公告）日：2012-03-22

  The present invention relates to a method for treating a disorder selected from depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R 1 , R 2 , Q, W, X, Y, m, and n are as defined in the specification, and their pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers and tautomeric forms. The invention also relates to novel compounds of formula I, compositions containing them, and methods for their preparation.

  本发明涉及一种治疗选自抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、与压力有关的障碍、精神病性障碍如精神分裂症、神经疾病如帕金森病、神经退行性疾病如阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用和代谢障碍如进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和吸收障碍、体温稳态障碍和功能障碍、睡眠和昼夜节律障碍以及心血管障碍的方法，包括向个体施用公式I化合物的治疗有效量，其中R1、R2、Q、W、X、Y、m和n在说明书中定义，以及它们的药物活性盐、混合物、对映体、光学异构体和互变异构体。本发明还涉及公式I的新化合物、含有它们的组合物以及其制备方法。
• BASHA, F. Z.;DEBERNARDIS, J. F., TETRAHEDRON LETT., 1984, 25, N 46, 5271-5274
  作者：BASHA, F. Z.、DEBERNARDIS, J. F.

  DOI：——

  日期：——
• NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES
  申请人：ENYO PHARMA

  公开号：US20210040059A1

  公开（公告）日：2021-02-11

  The present invention relates to a new class of non-fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.
• A novel three carbon-amino grignard reagent: its use in an efficient pyrrolidine synthesis
  作者：Fatima Z. Basha、John F. DeBernardis

  DOI：10.1016/s0040-4039(01)81581-1

  日期：——

  A novel primary amino protected Grignard reagent has been developed; 2,2,5,5-tetramethyl-1-aza-2,5-disilacyclopentane-1-propyl magnesium bromide 1a. Its usefulness is illustrated in the synthesis of 2-substituted pyrrolidines.

  已经开发了一种新型的伯氨基保护的格氏试剂。2,2,5,5-四甲基-1-氮杂-2,5-二硅环戊烷-1-丙基溴化镁1a。在2-取代的吡咯烷的合成中说明了其有用性。